SPS
SYRE icon

Susquehanna Portfolio Strategies’s Spyre Therapeutics SYRE Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.68M Hold
53,101
– – 0.04% 427
2025
Q4 		$1.74M Buy
53,101
+31,362
+144% +$819K 0.03% 528
2025
Q3 		$364K Buy
+21,739
New +$354K 0.01% 898

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Susquehanna Portfolio Strategies's SYRE Position: Q1 2026 in Review

Susquehanna Portfolio Strategies held its Spyre Therapeutics (SYRE) position steady in Q1 2026 at 53,101 shares worth $2.68M. The position accounts for 0.04% of the portfolio, ranked #427.

Susquehanna Portfolio Strategies first reported a position in SYRE in Q3 2025 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Susquehanna Portfolio Strategies held 53,101 shares of Spyre Therapeutics worth $2.68M as of Q1 2026.
  • Susquehanna Portfolio Strategies left its Spyre Therapeutics share count unchanged in Q1 2026.
  • Spyre Therapeutics made up 0.04% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #427 holding.
  • Susquehanna Portfolio Strategies first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.